Therapies Development Targeting β-Lactamases of Enterobacterales
In the battle against antibiotic resistance, the development of therapies targeting β-lactamases of Enterobacterales is of paramount importance. By utilizing enzyme inhibitors, β-lactamase-resistant antibiotics, and combination therapies, we can overcome the challenges posed by these highly adaptable enzymes. Ace Therapeutics is committed to pushing the boundaries of scientific innovation and delivering novel solutions to combat antibiotic resistance.
Introduction to β-Lactamases of Enterobacterales
Enterobacterales possess a wide array of β-lactamases, classified into different groups based on their molecular structures and substrate profiles. The most clinically relevant β-lactamase groups include the extended-spectrum β-lactamases (ESBLs), AmpC cephalosporinases, and carbapenemases. Each group exhibits unique characteristics, making them challenging targets for therapeutic intervention.
Fig. 1 Structures of β-lactam antibiotics and β-lactamase inhibitors. (Castanheira M, et al., 2021)
Various Therapies Targeting β-Lactamases of Enterobacterales
- Enzyme inhibitors. These inhibitors act by binding to the β-lactamase enzyme, preventing it from hydrolyzing β-lactam antibiotics. By combining an inhibitor with a β-lactam antibiotic, the efficacy of the antibiotic can be restored.
- β-lactamase-resistant antibiotics. An intriguing and innovative strategy emerges - the development of β-lactam antibiotics endowed with structural modifications that confer formidable resistance against the hydrolytic actions of these enzymes.
- Combination therapies. Combining different antibiotics or antibiotic classes has been an effective strategy to combat β-lactamase-mediated resistance. By utilizing multiple drugs with distinct mechanisms of action, the likelihood of bacterial resistance can be minimized.
What We Offer
At Ace Therapeutics, we recognize the urgent need for innovative therapies targeting β-lactamases of Enterobacterales. Our commitment to addressing antibiotic resistance drives us to offer a range of services and expertise to support the development of effective treatments.
Customized drug development solutions
Recognizing the diverse needs of our clients, we offer customized drug development solutions tailored to specific requirements. Whether it's designing and optimizing inhibitors, modifying existing antibiotics, or developing combination therapies, our team collaborates closely with clients to deliver personalized solutions to combat β-lactamase-mediated resistance.
Collaborative Research Partnerships
We actively seek collaborations with academic institutions, pharmaceutical companies, and research organizations to foster innovation and drive progress in the field of β-lactamase-targeted therapies. By pooling our collective expertise and resources, we can accelerate the development of novel treatments and contribute to the global effort against antibiotic resistance.
Service Highlights
- High-throughput screening. Our comprehensive screening assays enable the rapid evaluation of compound libraries, facilitating the discovery of promising therapeutic candidates.
- Structural biology and computational modeling. We employ advanced techniques in structural biology and computational modeling to gain insights into the mechanisms of β-lactamase action and identify potential drug targets. By understanding the structural details of these enzymes, we can design inhibitors and modified antibiotics with enhanced efficacy.
- In vitro and in vivo evaluations. Our in vitro and in vivo evaluation services allow for the rigorous testing of therapeutic candidates against β-lactamases produced by Enterobacterales. Through these evaluations, we assess the potency, pharmacokinetics, and safety profiles of the developed therapies
If you have a good idea and are looking for a reliable partner, please do not hesitate to contact us.
References
- Castanheira M, et al. Extended-spectrum β-lactamases: An update on their characteristics, epidemiology and detection. JAC-antimicrobial resistance, 2021, 3(3): dlab092.
- Tompkins K and van Duin D. Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions. European Journal of Clinical Microbiology & Infectious Diseases, 2021, 40(10): 2053-2068.